Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10220090 BCMA Antigen binding proteins

Patent 10220090 was granted and assigned to Amgen on March, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

March 5, 2019

Patent Application Number

14967167

Date Filed

December 11, 2015

Patent Citations Received

US Patent 11987633 Cross-species-specific single domain bispecific single chain antibody

0

US Patent 11434302 Bispecific T cell engaging antibody constructs

US Patent 11447567 Antibody constructs for FLT3 and CD3

US Patent 11884720 Antibody constructs for MSLN and CD3

0

US Patent 10683351 Antibody constructs for DLL3 and CD3

US Patent 10781264 PSMA and CD3 bispecific T cell engaging antibody constructs

US Patent 10981998 Cross-species-specific single domain bispecific single chain antibody

US Patent 11591396 Antibody constructs for DLL3 and CD3

...

Patent Primary Examiner

Patent abstract

The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10220090 BCMA Antigen binding proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool